Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Realmind: A Prospective and Retrospective Study to Characterize Real-World Use of Tafasitamab Plus Lenalidomide in US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, with a Focus on Patients from Minority Groups

Elizabeth A. Brem, John M. Burke, Mirko Vukcevic, Pia Kloepfer, Kimberly Saverno, Haifaa Abdulhaq, Andrew M Evens, Pierluigi Porcu, Mazyar Shadman, Christopher R. Flowers

Blood (2023) 142 (Supplement 1): 6251.

https://doi.org/10.1182/blood-2023-188482

Published: 2023

Journal Articles

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, Martin Dreyling, Gianluca Gaidano, Nagesh Kalakonda, Eva Maria Gonzalez Barca, Anna Marina Liberati, Zsolt Nagy, Daniel Moik, Mirko Vukcevic, Aasim Amin, Abhishek Bakuli

Blood (2023) 142 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2023-174043

Published: 2023

Journal Articles

Realmind: A Prospective, Multicenter, Observational Study of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second- or Third-Line Therapy and Not Receiving Autologous Stem Cell Transplant

Christopher R. Flowers, John M. Burke, Mirko Vukcevic, Susan Snodgrass, Shreekant Parasuraman, Thomas Büchele, Nuwan C. Kurukulasuriya

Blood (2021) 138 (Supplement 1): 5010.

https://doi.org/10.1182/blood-2021-148292

Published: 2021

Journal Articles

Preferences and Perceptions Regarding Treatment Decision-Making for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Mallory Yung, Frederick Schnell, Mirko Vukcevic, Nuwan C. Kurukulasuriya

Blood (2021) 138 (Supplement 1): 1928.

https://doi.org/10.1182/blood-2021-146594

Published: 2021